Identification of CDK2 as a Novel Target in Treatment of Prostate Cancer

References

• Ito K . Prostate cancer in Asian men. Nat. Rev. Urol.11(4), 197–212 (2014).
   PubMed Web of Science ®Google Scholar
• Chen Y , ZhangQ, WangQet al. Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progression. Sci. Rep.7(1), 4538 (2017).
   PubMedGoogle Scholar
• Manca P , PantanoF, IulianiMet al. Determinants of bone specific metastasis in prostate cancer. Crit. Rev. Oncol. Hematol.112, 59–66 (2017).
   PubMed Web of Science ®Google Scholar
• Chandrasekar T , YangJC, GaoAC, EvansCP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl. Androl. Urol.4(3), 365–380 (2015).
   PubMed Web of Science ®Google Scholar
• Gravis G , FizaziK, JolyFet al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15), a randomized: open-label: Phase III trial. Lancet Oncol.14(2), 149–158 (2013).
   PubMed Web of Science ®Google Scholar
• Lin PH , KuoWH, HuangACet al. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget7(7), 8310–8320 (2016).
   PubMedGoogle Scholar
• Yang Q , PanW, QianL. Identification of the miRNA-mRNA regulatory network in multiple sclerosis. Neurol. Res.39(2), 142–151 (2017).
   PubMed Web of Science ®Google Scholar
• Cerami E , GaoJ, DogrusozUet al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov.2(5), 401–404 (2012).
   PubMed Web of Science ®Google Scholar
• Gao J , AksoyBA, DogrusozUet al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal.6(269), pl1 (2013).
   PubMed Web of Science ®Google Scholar
• Malumbres M , BarbacidM. Cell cycle: CDKs and cancer: a changing paradigm. Nat. Rev. Cancer9(3), 153–166 (2009).
   PubMed Web of Science ®Google Scholar
• Bacevic K , LossaintG, AchourTN, GeorgetV, FisherD, DulicV. CDK2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage. Sci. Rep.7(1), 13429 (2017).
   PubMedGoogle Scholar
• Rizzolio F , TuccinardiT, CaligiuriI, LucchettiC, GiordanoA. CDK inhibitors: from the bench to clinical trials. Curr. Drug Targets11(3), 279–290 (2010).
   PubMed Web of Science ®Google Scholar
• Broad Institute . https://software.broadinstitute.org/morpheus/.
   Google Scholar
• Huang Da W , ShermanBT, LempickiRA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc.4(1), 44–57 (2009).
   PubMed Web of Science ®Google Scholar
• Szklarczyk D , MorrisJH, CookHet al. The STRING database in 2017: quality-controlled protein-protein association networks: made broadly accessible. Nucleic Acids Res.45(D1), D362–D368 (2017).
   PubMed Web of Science ®Google Scholar
• Szklarczyk D , FranceschiniA, WyderSet al. STRING v10: protein–protein interaction networks: integrated over the tree of life. Nucleic Acids Res.43, D447–D452 (2015).
   PubMed Web of Science ®Google Scholar
• Xu Z , ZhouY, CaoY, DinhTL, WanJ, ZhaoM. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Med. Oncol.33(11), 130 (2016).
   PubMed Web of Science ®Google Scholar
• Ho TT , ZhouN, HuangJet al. Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res.43(3), e17 (2015).
   PubMed Web of Science ®Google Scholar
• Chen B , DuanL, YinG, TanJ, JiangX. miR-381: a novel intrinsic WEE1 inhibitor: sensitizes renal cancer cells to 5-FU by upregulation of CDC2 activities in 786-O. J. Chemother.25(4), 229–238 (2013).
   PubMed Web of Science ®Google Scholar
• Chen B , LiuJ, HoTT, DingX, MoYY. ERK-mediated NF-kappaB activation through ASIC1 in response to acidosis. Oncogenesis5(12), e279 (2016).
   PubMedGoogle Scholar
• Shannon P , MarkielA, OzierOet al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res.13(11), 2498–2504 (2003).
   PubMed Web of Science ®Google Scholar
• Spangle JM , RobertsTM, ZhaoJJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim. Biophys. Acta1868(1), 123–131 (2017).
   PubMed Web of Science ®Google Scholar
• Ceder Y , BjartellA, CuligZ, RubinMA, TomlinsS, VisakorpiT. The molecular evolution of castration-resistant prostate cancer. Eur. Urol. Focus2(5), 506–513 (2016).
   PubMedGoogle Scholar
• Peng C , ZengW, SuJet al. Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway. Oncogene35(9), 1170–1179 (2016).
   PubMed Web of Science ®Google Scholar
• Mccurdy SR , PacalM, AhmadM, BremnerR. A CDK2 activity signature predicts outcome in CDK2-low cancers. Oncogene36(18), 2491–2502 (2017).
   PubMed Web of Science ®Google Scholar
• Kokontis JM , LinHP, JiangSSet al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of CDK2: CyclinA: and Skp2. PLoS ONE9(10), e109170 (2014).
   PubMed Web of Science ®Google Scholar
• Yu H , PardollD, JoveR. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer9(11), 798–809 (2009).
   PubMed Web of Science ®Google Scholar
• Qi W , GaoS, ChuJ, ZhouL, WangZ. Negative androgen-response elements mediate androgen-dependent transcriptional inhibition of TGF-beta1 and CDK2 promoters in the prostate gland. J. Androl.33(1), 27–36 (2012).
   PubMedGoogle Scholar
• Lee E , SonJE, ByunSet al. CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth. Toxicol. Appl. Pharmacol.272(1), 12–20 (2013).
   PubMed Web of Science ®Google Scholar
• Yin H , LoweryM, GlassJ. In prostate cancer C/EBPalpha promotes cell growth by the loss of interactions with CDK2: CDK4: and E2F and by activation of AKT. Prostate69(9), 1001–1016 (2009).
   PubMed Web of Science ®Google Scholar
• Yang ES , BurnsteinKL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and CDK2 mislocalization to the cytoplasm. J. Biol. Chem.278(47), 46862–46868 (2003).
   PubMed Web of Science ®Google Scholar